ANI Pharmaceuticals Inc (ANIP)vsViatris Inc (VTRS)
ANIP
ANI Pharmaceuticals Inc
$74.07
+1.04%
HEALTHCARE · Cap: $1.66B
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 1519% more annual revenue ($14.30B vs $883.37M). ANIP leads profitability with a 8.9% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.14. ANIP earns a higher WallStSmart Score of 57/100 (C).
ANIP
Buy57
out of 100
Grade: C
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-237.7%
Fair Value
$22.58
Current Price
$74.07
$51.49 premium
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 29.6% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Earnings declined 16.9%
Distress zone — elevated risk
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ANIP
The strongest argument for ANIP centers on Price/Book, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum. PEG of 1.06 suggests the stock is reasonably priced for its growth.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : ANIP
The primary concerns for ANIP are Market Cap, Piotroski F-Score, EPS Growth.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ANIP profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.80 — expect wider price swings.
ANIP is growing revenue faster at 29.6% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
ANIP scores higher overall (57/100 vs 50/100) and 29.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ANI Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?